

RESEARCH ARTICLE

Open Access

# Danning tablets attenuates $\alpha$ -naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes

Lili Ding<sup>1,2</sup>, Binfeng Zhang<sup>1,2</sup>, Changsen Zhan<sup>1,3</sup>, Li Yang<sup>1,2\*</sup> and Zhengtao Wang<sup>1,2\*</sup>

## Abstract

**Background:** The Danning tablets (DNts) is commonly prescribed in China as a cholagogic formula. Our previous studies showed that DNts exerted the protective effect on  $\alpha$ -naphthylisothiocyanate (ANIT)-induced liver injury with cholestasis in a dose-dependent manner. However, the detailed molecular mechanisms of DNts against ANIT-induced cholestasis are still not fully explored.

**Methods:** Danning tablet (3 g/kg body weight/day) was administered orally to experimental rats for seven days before they were treated with ANIT (60 mg/kg daily via gastrogavage) which caused cholestasis. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (T-Bil), direct bilirubin (D-Bil) and total bile acid (TBA) were measured to evaluate the protective effect of Danning tablet at 12, 24 and 48h after ANIT treatment. Meanwhile, total bilirubin or total bile acid in the bile, urine and liver were also measured at 48h after ANIT treatment. Furthermore, the hepatic or renal mRNA and protein levels of metabolic enzymes and transports were investigated to elucidate the protective mechanisms of Danning tablet against ANIT-induced cholestasis.

**Results:** In this study, we found that DNts significantly attenuated translocation of multidrug resistance-associated protein 2 (Mrp2) from the canalicular membrane into an intracellular and up-regulated the hepatic mRNA and protein expressions of metabolic enzymes including cytochrome P450 2b1 (Cyp2b1) and uridine diphosphate-5 $\alpha$ -glucuronosyltransferase (Ugt1a1) and transporters including bile salt export pump (Bsep) and multidrug resistance protein 2 (Mdr2) as well as renal organic solute transporter beta (Ost $\beta$ ), accompanied by further increase in urinary and biliary excretion of bile acid and bilirubin.

**Conclusions:** DNts might promote bile acid and bilirubin elimination by regulating the expressions of hepatic and renal transporters as well as hepatic metabolic enzymes.

**Keywords:** Danning tablet,  $\alpha$ -naphthylisothiocyanate (ANIT), Cholestasis, Transporter, Metabolic enzyme

## Background

Cholestasis, an impairment or cessation in the flow of bile, leads to hepatic and systemic accumulation of potentially toxic biliary compounds such as bile acids and bilirubin, resulting in acute liver toxicity, jaundice and hypercholesterolemia, and then aggravated outcomes just like hepatic fibrosis, cirrhosis and clinical signs of liver failure [1,2]. It has been reported that cholestasis may develop from viral

hepatitis or the administration of certain drugs and hormones or mechanical obstructions in the extrahepatic bile ducts [2].

The mechanisms of cholestasis might be related to the altered expressions of hepatic metabolic enzymes and transporters [3,4]. Drug metabolic enzymes (DMEs) play central roles in the metabolism, elimination and/or detoxification of xenobiotics or exogenous compounds introduced into the body [5]. Metabolic enzymes in the liver are classified into phase 1, such as cytochrome P450 (Cyp) [5], and phase 2, such as uridine diphosphate-5 $\alpha$ -glucuronosyltransferase (Ugt) [6], sulfotransferase (Sult)

\* Correspondence: yangli7951@hotmail.com; wangzht@hotmail.com

<sup>1</sup>The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of Traditional Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China  
Full list of author information is available at the end of the article

[7]. Several transporters which are related to cholestasis have been identified in hepatocytes, such as multidrug resistance protein (Mdr), bile salt export pump (Bsep), multidrug resistance associated protein (Mrp) [8,9], organic solute transporter alpha/beta (Osta $\alpha$ / $\beta$ ) [10], Na<sup>+</sup> taurocholate cotransporting polypeptide (Ntcp) [9], and organic anion transporting polypeptide (Oatp) [11].

ANIT is well known as a cholestatic compound and has been widely used as a model component for induction of intrahepatic cholestasis [12]. In rodents,  $\alpha$ -naphthylisothiocyanate (ANIT) is a widely used chemical to mimic human intrahepatic cholestasis [13]. It has been reported that the mRNA expressions of metabolic enzymes and transporters changed in ANIT-induced cholestasis model [14,15].

Danning tablets (DNts), as a composite prescription of traditional Chinese medicine, consisting of seven medicinal materials: *Radix et Rhizoma Rhei*, *Rhizoma et Radix Polygoni Cuspidati*, *Pericarpium Citri Reticulatae*, *Pericarpium Citri Reticulatae Viride*, *Radix Curcumae*, *Fructus Crataegi* and *Rhizoma Imperatae* [16], have been proved to be effective for treatment of cholecystitis and prevention the formation of cholesterol gallstone in human [17]. We previously showed that the protective effect of DNts on ANIT-induced liver injury was probably due to its attenuation of oxidative stress disruption in the liver tissues and neutrophil infiltration [18]. However, the underlying mechanisms about protective effect of DNts on ANIT-induced cholestasis are not explored yet.

In this study, in order to clarify the possible mechanisms for protective effect of DNts on ANIT-induced cholestasis, we investigated the mRNA and protein expressions of metabolic enzymes and transports which were relevant to the excretion of bile acids and bilitubin.

## Methods

### Drugs, chemicals and reagents

DNts were friendly provided by Shanghai Hutchison Pharmaceuticals (Shanghai, China) at July 2010. Standard compounds (emodin, aloe-emodin, rhein, chrysophanol, physcion) purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). ANIT were purchased from Sigma-Aldrich (St. Louis, USA). The purity of each compound was determined to be above 98% by HPLC analysis. Ammonium acetate, formic acid, acetonitrile and methanol (HPLC-grade) were purchased from Fisher Scientific (Nepean, Ont., Canada). Ultrapure water was prepared by a Milli-Q50 SP Reagent Water System (Millipore Corporation, MA, USA) for the preparation of samples and buffer solutions. Serum levels of ALT, AST, ALP, T-Bil, D-Bil and TBA were determined using a commercially available test kits (SHINO-TEST Corporation, Japan) with HITACHI

7080 Automatic Analyzer system (Japan). All other chemicals and solvents used were of analytical grade.

### Chromatography analysis

In order to make quality control of DNts and improve the repeatability of experiments, the contents of five anthraquinones, which might be the main active components contained in DNts, were determined by HPLC analysis. The determination was performed on the Agilent 1100 chromatographic system, consisting of a solvent degasser, aquaternary gradient pump before column, diodearray detector (DAD) and a data station with analytical software of Chemstation 8.03 (Agilent, Inc., USA). The method to analyze the anthraquinones in DNts used in this study was well established according to the China Pharmacopoeia Committee (2010 edition) [15]. All the separation was performed on a Kromasil<sup>®</sup> C18 analytical column (250 mm  $\times$  4.6 mm, 5  $\mu$ m) and maintained at 25°C. The mobile phase was a mixture of methanol–0.1% phosphoric acid aqueous solution (85:15, v:v) with the flow rate of 1ml/min. The injection volume was 10  $\mu$ l and the detection wavelength was set at 254 nm. The standard solutions of five AQs (aloe-emodin 15  $\mu$ g/mL, emodin 8  $\mu$ g/mL, chrysophanol 40  $\mu$ g/mL, rhein 2  $\mu$ g/mL and physcion 10  $\mu$ g/mL) were prepared with methanol. Samples were prepared according to China Pharmacopoeia Committee, 2010.

### Animal experimental design

Male Wistar rats weighing 220  $\pm$  20 g were used in this study. All rats were maintained in 12-h light/dark cycles and given free access to water and standard chow. All animal care and use procedures were in accordance with the guidelines of the Institutional Animal Care and Use Committee and were approved by the Animal Experimentation Ethics Committee at the Shanghai University of Traditional Chinese Medicine under the guidelines of the National Health and Medical Research Council of China. The animals were randomly divided into the following treatment groups (n = 8 rats/group): (1) Control group (Vehicle group), (2) ANIT group, (3) DNts + ANIT group, (4) DNts group. The rats in Control and ANIT groups were pretreated with 0.5% sodium carboxymethylcellulose (CMCNa) solution alone; the other two groups were intragastrically treated daily with the powder of DNts which was suspended in 0.5% CMCNa solution at a dose of 3.0 g/kg B.W. for 9 consecutive days, respectively. At 12 h after the seventh administration of test drugs, groups 2 and 3 were intragastrically received ANIT dissolved in peanut oil at a dose of 60 mg/kg B.W.. The Control and DNts groups were intragastrically given the peanut oil in an equal volume as for groups 2 and 3 (5 ml/kg B.W.). Blood samples were collected from inferior vena cava at 0, 12, 24, and 48 h after ANIT

administration and separated, and then stored at  $-80^{\circ}\text{C}$  for later analysis of biochemical parameters.

At 48 h post ANIT administration, the rats were anaesthetized with urethane (1 g/kg B.W., i.p.). The bile duct was cannulated with Closed IV Catheter System (inner diameter, 0.36 mm; outer diameter, 0.71 mm; Becton, Dickinson and Co., Suzhou, China). After the operation, Bile specimens were collected into tubes for 1 h, as previously described [18]. Then, the animals were killed by decapitation, the liver and kidney of rats were collected and stored in liquid nitrogen for analysis of enzyme levels and gene or protein expressions.

#### Serum biochemistry analysis

Serum was collected at 0, 12, 24, 36 and 48 h after ANIT treatment. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBil), direct bilirubin (DBil) and total bile acid (TBA) were determined using commercially available clinical test kits and an automatic biochemical analyzer (HITACHI 7080, Japan).

#### Bile acid and bilirubin analysis

Bile acids were extracted from liver samples using 75% ethanol, as previously described [19]. Total bile acids in the liver, bile, and urine were measured using commercial assay kits from the Jiancheng Institute of Biotechnology (Nanjing, China). Total bilirubin in the bile and urine were also measured with commercial assay Kits from the Jiancheng Institute of Biotechnology (Nanjing, China) in accordance with the manufacturer's protocols.

#### Quantitative real-time PCR analysis

Total RNA from liver and kidney were extracted using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer's instructions. Quantitative real-time PCR (qPCR) was performed using cDNA generated from 3  $\mu\text{g}$  total RNA with the SuperScript II Reverse Transcriptase kit (Invitrogen, CA, USA). PCR reactions were carried out using SYBR Premix ExTaq Mix (Takara Biotechnology, Japan) in an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, CA). The primer sequences were listed in Table 1. Thermal cycler parameters were as follows: 1 cycle of  $95^{\circ}\text{C}$  for 30 s, 40 cycles of denaturation ( $95^{\circ}\text{C}$ , 5 s) and combined annealing/extension ( $60^{\circ}\text{C}$ , 30 s). Gene expression changes were calculated by the comparative Ct method and the values were normalized to endogenous reference Gapdh.

#### Preparation of liver membranes and for Western analysis

Plasma membranes or intracellular microsomal membranes were separated by differential centrifugation. Portions of the liver were homogenized with a teflon pestle (20 strokes at 3,000 rpm) in 0.3 mol/L sucrose containing

0.1 mmol/L PMSF, 25  $\mu\text{g}/\text{mL}$  leupeptin, 5  $\mu\text{g}/\text{mL}$  aprotinin, and 5  $\mu\text{g}/\text{mL}$  pepstatin A (50 mg liver/mL buffer) according previous report [20]. The homogenate was used for membrane preparation as described previously [21]. Protein concentrations were measured according to the method of BCA [22] using bovine serum albumin as a standard.

#### Western blot studies

Immunoblotting and subsequent densitometry were performed with mixed plasma membranes, and intracellular membranes were incubated with antibodies against Mrp2 (ab3373, 1:50, abcam) and  $\text{Na}^+/\text{K}^+$ -ATPase (#3010, 1:1000, Cell Signaling). Moreover, the crude membranes were prepared according to the protocol of protein extraction kit (BioVision, USA). Equal amounts of crude membranes (40  $\mu\text{g}/\text{lane}$ ) were separated on 6%-15% SDS-PAGE and transferred to nitrocellulose membrane. Membranes were blocked in 5% skim milk and incubated with antibodies against Bsep (sc-25571, 1:200, Santa Cruz), Ntcp (#6522-1, 1:1000, epitomics), Oatp1 (LS-C113034-50, 1:1000, Life-Span BioSciences), Mrp3(ab3375, 1:50, abcam), Mdr2 (SAB2100008, 1:1000, sigma) and  $\text{Na}^+/\text{K}^+$ -ATPase (#3010, 1:1000, Cell Signaling), respectively. Blots were incubated with horseradish peroxidase conjugated secondary antibodies (Santa Cruz) and developed by ECL detection reagents (Amersham). The protein bands were quantified by the average ratios of integral optic density (IOD) following normalization to  $\text{Na}^+/\text{K}^+$ -ATPase expression.

#### Determination of liver Ugt1a1, Cyp2b1 and Sult2a1 levels

Liver segments were homogenized in ice-cold PBS. The homogenates were centrifuged at 3,000 g for 10 min and the supernatants were assayed for the determination of levels of the Ugt1a1, Cyp2b1 (CUSABIO, CN) and Sult2a1 (USCN Life Science, CN) by using ELISA kits according to the manufacturer's protocols. The results are expressed as folds of control.

#### Statistical analysis

The data were analyzed using a SPSS 16.0 statistical package. Multiple comparisons were performed by one-way analysis of variance (ANOVA) followed by LSD t-test. Difference was considered statistically significant when  $p \leq 0.05$ , and very significant when  $p \leq 0.01$  and  $p \leq 0.001$ . All results are presented as the mean  $\pm$  SD.

## Results

#### HPLC determination of anthraquinones in DNts

The major compounds in DNts were anthraquinones and analyzed with HPLC-UV. By referring to standards, HPLC chromatogram analysis of three batches of DNts showed that the main anthraquinones in DNts were aloemodin, emodin, chrysophanol and physcion (Figure 1);

**Table 1 Primer sequences used for quantitative real-time PCR in this study**

Gene	(GenBank accession no.)	Sequence (5'-3')
Asbt	XM_003751634	GGATAGATGGTGACATGGAC (fw) GAAACAGGAATAACAAGCGC (rev)
Bsep	U69487	CTGATGCTTATGGGAGGCGTAT (fw) TCTGGTGAAGGAGCTGTTGATC (rev)
Cyp2b1	NM_001134844	GCTATGGTTTCTGCTGATGCTC (fw) GACTCTGTGTGTTACTCCAATAGGG (rev)
Mdr2	NM_012690	GTTGAAATGAAAATGTTGGCTGG (fw) ATGCCGTAGATGTGAGCCTTCC (rev)
Mrp2	NM_012833	TCAGATGAGGAGTTTGAGAGGG (fw) CTCTGTCACTTCGGATAACAACCC (rev)
Mrp3	NM_080581	TGAAGAGACTGGAATCCGTTAGCC (fw) GTTGGAGGCGATGTAAGGATAAGTG (rev)
Mrp4	NM_133411	GACACCAAAAACGCGAACGG (fw) ACAAGGACATAGAACCACGAGG (rev)
Ntcp	NM_017047	CTACCTCCTCCCT GATGCCCTT (fw) TGAGGATGGTAGACAGAGTTGAATG (rev)
Oatp1	NM_017111	TGCCTGCCTTCTTATTCTGATACT (fw) GTTTTCAGTTCTCCGTCATTCTCG (rev)
Osta	NM_001107087	TCCTCTGCCCTGAGCCTTATC (fw) TCTCTGCTTACCATTATTACAA (rev)
Ostβ	XM_238546	TGCTTTGGTATTTCGGTTC (fw) TCTGGCATTCCGTTGTCTT (rev)
Sult2a1	NM_131903	ATCAAAAAGAAAGGACCACGACTC (fw) AACCATTCAACATAAGTTCCAGTG (rev)
Ugt1a1	NM_012683	TGAAGCCTATGTCAACGCCTC (fw) CGATGGTCTAGTCCGGTGTAGC (rev)
Gapdh	NM_017008	AGAAGGTGGTGAAGCAGGCATC (fw) CGAAGGTGGAAGAGTGGGAGTTG (rev)

fw: forward primer; rev: reverse primer; bp: base pair.

the contents of these components were 0.445 mg/g, 13.452 mg/g, 1.341 mg/g, and 2.290 mg/g, respectively, and summarized in Table 2.


#### Effects of DNts on the levels of serum enzymes and components in ANIT-induced cholestasis rats

To examine the effects of DNts on ANIT mediated hepatotoxicity and cholestasis, plasma levels of ALT, AST, ALP, TBil, DBil and TBA were quantified as measures of liver injury with cholestasis. In both ANIT group and DNts + ANIT group, serum levels of ALT, AST, ALP, TBIL, DBIL and TBA were unchanged at 12 h, but significantly elevated at 24 h and 36 h and peaked at 48 h after ANIT treatment as compared to those in the vehicle group. However, the pretreatment of DNts at dose of 3 g/kg B.W. significantly reversed ANIT-induced elevation of TBIL (Figure 2;  $p < 0.01$ ) at 36 h as well as ALT, AST, ALP, TBIL, DBIL and TBA (Figure 2;  $p < 0.01$ ) at

48 h after ANIT treatment. In addition, DNts treated alone (3 g/kg B.W.) did not significantly affect serum ALT, AST, ALP, TBil, DBil and TBA levels as compared to the vehicle group (Figure 2). The above results are consistent with our previous report [18].

#### Effects of DNts on the levels of bile acids and bilirubin in the liver, urine, and bile after ANIT treatment

The concentrations of bile acid or bilirubin in the liver, bile, and urine were quantified at 48 h after ANIT treatment. Hepatic bile acid pool size were increased significantly in ANIT-treated rats (Figure 3A;  $p < 0.01$ ). Meanwhile, urinary excretion of bile acids and bilirubin in the rats of ANIT-treated group were also increased after ANIT treatment (Figure 3D, 3E;  $p < 0.01$ ). In addition, biliary bilirubin concentrations in ANIT-treated rats were elevated significantly (Figure 3C;  $p < 0.01$ ). In contrast, biliary bile acid pool size were dramatically reduced by



ANIT-treatment (Figure 3B;  $p < 0.01$ ). DNts pretreatment significantly attenuated the ANIT-induced accumulation of hepatic bile acids and significantly increased the bile acid and bilirubin excretion of urine and bile in ANIT-

intoxicated rats (Figure 3A-3E;  $p < 0.01$ ,  $p < 0.05$ ). DNts treated alone (3 g/kg B.W.) did not significantly affect the bile acid and bilirubin pool size in the liver, bile and urine as compared to the vehicle group (Figure 3). These

**Table 2 The contents of five anthraquinones in DNts**

Compound	RT	Content (mg/g)	SD
Aleo-emodin	4.774	0.445	0.035
Emodin	9.439	13.452	0.843
Chrysophanol	13.799	1.341	0.094
Physcion	19.255	2.290	0.168
Rhein	-	-	-

RT:retention time.

findings suggested that DNts pretreatment stimulates bile acid and bilirubin elimination to attenuate cholestasis.


**Effects of DNts on gene expressions of transporter and metabolic enzyme in ANIT-induced cholestasis rats**

Firstly, we examined hepatic mRNA expressions of basolateral transporters after ANIT treatment (Figure 4A). In agreement with previous observations [14,15], the mRNA levels of basolateral uptake transporters Ntcp and Oatp1 were significantly down-regulated by ANIT (Figure 4A;  $p < 0.01$ ). In contrast, the mRNA levels of basolateral efflux transporter Mrp3, MRP4, Ost $\beta$  were markedly up-regulated in ANIT-intoxicated rats (Figure 4A, 4B;  $p < 0.01$ ). However, Both ANIT and DNts did not affect the mRNA expressions of Ost $\alpha$  (Figure 4B). DNts pretreatment significantly reversed ANIT-induced down-regulation of the Ntcp ( $p < 0.05$ ) and Oatp1 mRNA levels ( $p < 0.01$ ), but did not affect the mRNA levels of Mrp3, Mrp4 and Ost $\beta$  in ANIT-intoxicated rats (Figure 4A, 4B).


Secondly, hepatic gene expressions of canalicular efflux transporters were determined (Figure 4B). The mRNA level of Mdr2 was significantly up-regulated by ANIT (Figure 4C;  $p < 0.01$ ). There were no changes in mRNA levels for Mrp2 and Bsep after ANIT treatment (Figure 4C). DNts pretreatment resulted in substantial elevation of Mdr2 and Bsep mRNA levels in ANIT-intoxicated rats (Figure 4C;  $p < 0.05$ ).

Thirdly, we examined the hepatic gene expressions of metabolic enzymes such as Cyp2b1, Ugt1a1 and Sult2a1 (Figure 4D). The mRNA levels of Cyp2b1 and Ugt1a1 in ANIT-treated rats were significantly decreased (Figure 4D;  $p < 0.01$ ). DNts pretreatment significantly reversed ANIT-induced reduction of the Cyp2b1 and Ugt1a1 mRNA levels (Figure 4D;  $p < 0.05$ ), but did not affect the mRNA expression of Sult2a1 in ANIT-intoxicated rats (Figure 4D). Otherwise, DNts pretreatment alone did not affect mRNA levels of Oatp1, Ntcp, Mrp3, Bsep, Mdr2, Mrp2, Cyp2b1, Ugt1a1 and Sult2a1 (Figure 4D).

In addition, as urinary excretion of bile acids and bilirubin were significantly higher in ANIT-intoxicated rats, we next determined the expression of renal bile acid transporters (Figure 5A-F). ANIT treatment markedly increased the mRNA levels for bile acid export transporter Mrp2, Mrp3, MRP4 and Ost $\beta$  (Figure 5A, 5B, 5C and 5F;  $p < 0.01$ ). In contrast, the main reuptake transporter Asbt was down-regulated after ANIT treatment (Figure 5D;  $p < 0.01$ ). Pretreatment with DNts resulted in further significantly increasing of renal Mrp3 and Ost $\beta$  mRNA levels and significantly reversing the



**Figure 2 Serum levels of (A) ALT, (B) AST, (C) ALP, (D) T-Bil, (E) D-Bil and (F) TBA were measured in each group at 0, 12, 24, 36 and 48 h after ANIT treatment.** Data represent means  $\pm$  S.D. (n = 8 for each group). Significant difference between two groups. \* $p < 0.05$ , \*\* $p < 0.01$  vs. control group; # $p < 0.05$ , ## $p < 0.01$  vs. the ANIT-treated group.



renal mRNA level of *Asbt* in ANIT-intoxicated rats (Figure 5B,F;  $p < 0.05$ ). Both ANIT and DNts treatment did not affect the mRNA expression of *Osta* (Figure 5E). DNts pretreatment alone did not affect the mRNA levels of renal *Mrp2*, *Mrp3*, *MRP4*, *Asbt*, *Osta* and *Osta* (Figure 5A-F).

#### Effect of DNts on protein expressions of *Ntcp*, *Oatp1*, *Mrp3*, *Mdr2*, *Bsep* and *Mrp2* in the liver membranes of ANIT-induced cholestasis rats

Furthermore, we investigated the protein expressions of hepatic transporters to confirm the results of mRNA levels. The protein levels of basolateral uptake transporter *Ntcp* and *Oatp1* were significantly downregulated in the liver membranes of ANIT-intoxicated rats (Figure 6;  $p < 0.01$ ). In contrast, the protein expression of basolateral efflux transporter *MRP3* was significantly up-regulated in the liver membranes of ANIT-intoxicated rats as well as the canalicular efflux transporter *Mdr2* (Figure 6;  $p < 0.01$ ). However, DNts pretreatment significantly up-regulated the protein levels of *Ntcp* and *Oatp1* (Figure 6;  $p < 0.01$ ,  $p < 0.05$ ) and further increased the protein levels of canalicular efflux transporter *Mdr2* and *Bsep* (Figure 6;  $p < 0.05$ ), but did not affect the protein level of *Mrp3* in the hepatic membranes of ANIT-intoxicated rats. Otherwise, both ANIT and DNts treatment did not affect the


protein level of *Mrp2* in hepatic plasma Membranes (Figure 7). Therefore, we evaluated whether ANIT could lead to redistribution of the protein *Mrp2* from plasma to intracellular membranes. *Mrp2* detection was increased in hepatic intracellular membranes of ANIT-intoxicated rats (Figure 7;  $p < 0.01$ ). DNts pretreatment significantly reversed ANIT-induced up-regulation of *Mrp2* in intracellular membranes (Figure 7;  $p < 0.01$ ).

#### Effect of DNts on the protein levels of *Cyp2b1*, *Ugt1a1* and *Sult2a1* in the liver of ANIT-induced cholestasis rats

The protein levels of endogenous metabolic enzymes in liver tissue microsomes was further confirmed. The protein levels of *Cyp2b1* and *Ugt1a1* in the model group were obviously reduced (Figure 8;  $p < 0.01$ ). But the hepatic *Sult2a1* level was not changed in ANIT-intoxicated rats (Figure 8). Whereas, DNts treatment notably reversed the decline of these metabolic enzymes except *Sult2a1* compared with that in ANIT-treated rats (Figure 8;  $p < 0.01$ ). Moreover, pretreatment of DNts alone did not affect the hepatic protein levels of *Cyp2b1*, *Ugt1a1* and *Sult2a1* (Figure 8).

#### Discussion

The pretreatment of DNts significantly reversed ANIT-induced elevation of serum ALT, AST, ALP, T-Bil, D-Bil






and TBA levels at 48h after ANIT treatment in consistent with previous research [23]. We presented here the evidence that DNts protected rats from the accumulation of bile acids in the liver and subsequent development of liver injury with cholestasis induced by ANIT, in association with an augmentation of bile acid and bilirubin excretion of bile and urine.

In the current study, we further investigated whether the protective effect of DNts against ANIT-induced cholestasis might be related to the expression of metabolic enzymes and transporters. The metabolic enzymes participate in critical processes including the biosynthesis of

bile acids and the detoxification of accumulating biliary compounds. The hepatic metabolic enzymes may render hydrophobic substrates less toxic and better soluble for biliary and urinary excretion via phase I hydroxylation and phase II conjugation to counteract cholestasis [24]. Our findings displayed that DNts pretreatment significantly up-regulated both mRNA and protein expressions of hepatic metabolic enzymes including Cyp2b1 and Ugt1a1 in ANIT-induced cholestasis rats. These results indicated that the up-regulation of mRNA and protein expressions of the phase I hydroxylation enzymes (Cyp2b1) and phase II conjugation enzymes








(Ugt1a1) induced by DNts might counteract cholestatic liver damage by detoxification of accumulating biliary compounds.

Basolateral uptake transporters, such as Ntcp and Oatps, transport bile acids and organic anions from sinusoidal blood into hepatocytes [9-11]. In contrast, basolateral export transporters, such as Mrp3, Mrp4 and Ostα/β transport bilirubin glucuronide and bile acids, respectively, from hepatocytes into blood during cholestasis [10,25]. Bile acids transport at canalicular membrane of the hepatocyte is mediated by ATP-binding cassette transporters, including Bsep, Mrp2, and Mdr2 [26]. The export of toxic bile acids by canalicular transporters is probably an alternative escape route during intrahepatic cholestasis [8]. At 48 h after ANIT treatment, we found that spontaneous hepatic anticholestatic defenses which comprised down-regulation of import systems (e.g., Ntcp, Oatp1) and adaptive induction of basolateral alternative export pump (e.g., Mrp3) as well as the canalicular transporters,

such as MDR2 were formed in ANIT- intoxicated rats. However, intrinsic hepatocellular adaptive induction of transporters in cholestasis is too weak to prevent ongoing liver injury [27]. Indeed, DNts pretreatment induced mRNA and protein expressions of hepatic canalicular export transporters Bsep and Mdr2, beyond what was seen following administration of ANIT alone. In addition, DNts reversed ANIT-induced down-regulation of mRNA and protein levels of Oatp1 and Ntcp for the attenuation of cholestasis has been performed.

Mrp2, which is another key canalicular transporter, belongs to ATP-binding cassette proteins localized to the canalicular domain of the hepatocyte. Recent studies have demonstrated that, Mrp2 undergoes endocytic retrieval from the canalicular membrane into an intracellular compartment in several models of cholestasis [20,28]. Our results showed that hepatic mRNA expression and protein levels of MRP2 did not changed in ANIT-treated rats. In contrast, Mrp2 in intracellular membranes was



significantly increased in ANIT-intoxicated rats. The lack of change of Mrp2 content in mixed plasma membranes in response to ANIT may be tentatively explained by the fact that intracellular accumulation of Mrp2 in enriched microsomal membranes represents a small fraction of the total amount of transporter in the cell according to previous report [20]. It is possible that the protective effects of DNts were through other alternative mechanisms for the elevation of renal and biliary excretion of bile acid and bilirubin with unchanged expression of total Mrp2 in the kidney and liver.

Furthermore, Liver disease is often accompanied by renal dysfunction. After ANIT treatment, renal mRNA expressions of Mrp2, Mrp3, Mrp4 and Ost $\beta$  were significantly up-regulated. In contrast, renal mRNA level of Asbt was significantly down-regulated, accompanied by increased concentrations of bile acid and bilirubin in urine. These results indicated that adaptive responses to cholestasis also occur in the kidney in an effort to eliminate excess bile acids and toxic compounds from circulation which is according with previous report [29]. In addition, DNts pretreatment further increased the renal mRNA level of Ost $\beta$  in ANIT-intoxicated rats, accompanied by further increase in urinary excretion of bile acid and bilirubin (Figure 7).

## Conclusions

In summary, Danning tablets provides protection from ANIT-induced cholestasis with liver injury through adaptive responses in both the kidney and liver that enhance the expressions of hepatic canalicular efflux transporters (Bsep and Mdr2), renal efflux transporter Ost $\beta$  and bile acid-detoxifying enzyme (Cyp2b1 and Ugt1a1) and attenuate the hepatic Mrp2 translocation, accompanied by further increase in urinary and biliary excretion of bile acid and bilirubin.

## Abbreviations

ANIT:  $\alpha$ -naphthylisothiocyanate; ALT: Alanine aminotransferase; AST: Aspartateaminotransferase; ALP: Alkaline phosphatase; TBIL: Total bilirubin; DBIL: Direct bilirubin; TBA: Total bile acid; DNts: Danning tablets; Cyp: Cytochrome P450; Ugt: Uridine diphosphate-5 $\beta$ -glucuronosyl transferase; Sult: Sulfotransferases; Ntcp: Na<sup>+</sup> taurocholate cotransporting polypeptide; Oatp: Organic anion-transporting polypeptide; Ost: Organic solute transporter; MRP: Multidrug resistance-associated protein; Bsep: Bile salt export pump; Mdr: Multidrug resistance protein; Asbt: Apical sodium dependent bile acid transporter; Gapdh: Glyceraldehyde-3-phosphate dehydrogenase; B.W.: Body weight.

## Competing interests

The authors declare that they have no competing interests with other people or organizations that can inappropriately influence their work. And there are no potential conflicts of interest including financial, employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications and registrations, and grants or other funding. In addition, there are no competing interests between Shanghai Hutchison Pharmaceuticals and Institute of Traditional Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine.

## Authors' contributions

ZW and LY, as the principal investigator, were responsible for the concept and design of the study. LD did the whole experiments of the study and wrote the manuscript. BZ and CZ conducted part of the experiments. All authors participated in the preparation of, and have approved the final version of the manuscript.

## Acknowledgements

This work is financially supported by the Natural Science Foundations of China (81073027, 81303186), Shanghai Rising-Star Program (09QA1405500), Shanghai Science and Technology Commission Project (10DZ1970200) and Scientific Innovation Project from Shanghai Municipal Education Commission (09YZ125) and China Postdoctoral Science Foundation (2013M531202).

## Author details

<sup>1</sup>The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of Traditional Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

<sup>2</sup>Shanghai R&D Center for Standardization of Traditional Chinese Medicines, Shanghai 201203, China. <sup>3</sup>Shanghai Hutchison Pharmaceuticals, Shanghai 201203, China.

Received: 14 January 2014 Accepted: 9 July 2014

Published: 17 July 2014

## References

1. Trauner M, Meier PJ, Boyer JL: **Molecular pathogenesis of cholestasis.** *N Engl J Med* 1998, **339**(17):1217–1227.
2. Boyer JL: **New perspectives for the treatment of cholestasis: Lessons from basic science applied clinically.** *J Hepatol* 2007, **46**(3):365–371.
3. Elferink RO: **Cholestasis.** *Gut* 2003, **52**(Suppl 2):ii42–ii48.
4. Kliewer SA, Willson TM: **Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor.** *J Lipid Res* 2002, **43**(3):359–364.
5. Meyer UA: **Overview of enzymes of drug metabolism.** *J Pharmacokinetics Biopharm* 1996, **24**(5):449–459.
6. Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD: **Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family.** *Drug Metab Dispos* 2003, **31**(3):326–333.
7. Banoglu E: **Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens.** *Curr Drug Metab* 2000, **1**(1):1–30.
8. Kerb R, Hoffmeyer S, Brinkmann U: **ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.** *Pharmacogenomics* 2001, **2**(1):51–64.
9. Stieger B: **The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation.** *Handb Exp Pharmacol* 2011, **201**:205–259.
10. Halilbasic E, Claudel T, Trauner M: **Bile acid transporters and regulatory nuclear receptors in the liver and beyond.** *J Hepatol* 2013, **58**(1):155–168.
11. Tirona RG, Kim RB: **Pharmacogenomics of organic anion-transporting polypeptides (OATP).** *Adv Drug Deliv Rev* 2001, **54**(10):1343–1352.
12. Becker BA, Plaa GL: **The nature of alpha-naphthylisothiocyanate-induced cholestasis.** *Toxicol Appl Pharmacol* 1965, **7**(5):680–685.
13. Plaa GL, Priestly BG: **Intrahepatic cholestasis induced by drugs and chemicals.** *Pharmacol Rev* 1976, **28**(3):207–273.
14. Tanaka Y, Aleksunes LM, Cui YJ, Klaassen CD: **ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling.** *Toxicol Sci* 2009, **108**(2):247–257.
15. Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD: **Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice.** *Toxicol Sci* 2009, **110**(1):47–60.
16. China Pharmacopoeia Committee: *Pharmacopoeia of the People's Republic of China, Vol. 1;* 2010:937.
17. Li KW, Ji F, Wang RR, Jiang H, Shi JW: **Pereventive effect and mechanism of danning tablet on the cholesterol gallstone.** *J Hepatopancreatobiliary Surg* 2004, **16**:24–48.
18. Ding LL, Zhang BF, Dou W, Yang L, Zhan CS, Wang ZT: **Protective effect of Danning tablet on acute liver injury with cholestasis induced by  $\alpha$ -naphthylisothiocyanate in rats.** *J Ethnopharmacol* 2012, **140**(2):222–229.

19. Chen X, Zhang C, Wang H, Xu J, Duan ZH, Zhang Y, Yu T, Wei W, Xu DX, Xu JM: **Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice.** *Toxicol Appl Pharmacol* 2009, **240**(1):26–36.
20. Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M: **Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis.** *Hepatology* 2002, **35**(6):1409–1419.
21. Marinelli RA, Pham L, Agre P, LaRusso NF: **Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane. Evidence for a secretin-induced vesicular translocation of aquaporin-1.** *J Biol Chem* 1997, **272**(20):12984–12988.
22. Hill HD, Straka JG: **Protein determination using bicinchoninic acid in the presence of sulfhydryl reagents.** *Anal Biochem* 1988, **170**(1):203–208.
23. Calvo JR, Reiter RJ, García JJ, Ortiz GG, Tan DX, Karbownik M: **Characterization of the protective effects of melatonin and related Indoles against  $\alpha$ -naphthylisothiocyanate-Induced liver injury in rats.** *J Cell Biochem* 2001, **80**(4):461–470.
24. Xu C, Li CY, Kong AN: **Induction of phase I, II and III drug metabolism/transport by xenobiotics.** *Arch Pharm Res* 2005, **28**(3):249–268.
25. Takikawa H: **Hepatobiliary transport of bile acids and organic anions.** *J Hepatobiliary Pancreat Surg* 2002, **9**(4):443–447.
26. Dean M, Hamon Y, Chimini G: **The human ATP-binding cassette (ABC) transporter superfamily.** *J Lipid Res* 2001, **42**(7):1007–1017.
27. Wagner M, Fickert P, Zollner G, Fuchsichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M: **Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.** *Gastroenterology* 2003, **125**(3):825–838.
28. Dombrowski F, Kubitz R, Chittattu A, Wettstein M, Saha N, Haussinger D: **Electromicroscopic demonstration of multidrug resistance protein 2 (Mrp2) retrieval from the canalicular membrane in response to hyperosmolarity and lipopolysaccharide.** *Biochem J* 2000, **348**(Pt 1):183–188.
29. Yang P, Chen P, Wang T, Zhan Y, Zhou M, Xia L, Cheng R, Guo Y, Zhu L, Zhang J: **Loss of A (1) adenosine receptor attenuates  $\alpha$ -naphthylisothiocyanate-induced cholestatic liver injury in mice.** *Toxicol Sci* 2013, **131**(1):128–138.

doi:10.1186/1472-6882-14-249

**Cite this article as:** Ding et al.: Danning tablets attenuates  $\alpha$ -naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes. *BMC Complementary and Alternative Medicine* 2014 **14**:249.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

